Cargando…

Prevalence and time course of arrhythmia-induced cardiomyopathy in patients with newly diagnosed heart failure and concomitant tachyarrhythmia – the TACHY-HF pilot trial

BACKGROUND: Arrhythmias may often be a result of heart failure, but they can also cause left-ventricular systolic dysfunction (LVSD), thereby presenting as arrhythmia-induced cardiomyopathy (AIC). AIC-diagnosis is established retrospectively when LVSD normalizes or improves significantly over time f...

Descripción completa

Detalles Bibliográficos
Autores principales: Schach, C, Koertl, T, Harler, B, Muehlbeck, F, Baum, P, Meindl, C, Lavall, D, Zeman, F, Koller, M, Resch, M, Baessler, A, Maier, L.S, Wachter, R, Sossalla, S.T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767587/
http://dx.doi.org/10.1093/eurheartj/ehab724.0762
_version_ 1784634766329380864
author Schach, C
Koertl, T
Harler, B
Muehlbeck, F
Baum, P
Meindl, C
Lavall, D
Zeman, F
Koller, M
Resch, M
Baessler, A
Maier, L.S
Wachter, R
Sossalla, S.T
author_facet Schach, C
Koertl, T
Harler, B
Muehlbeck, F
Baum, P
Meindl, C
Lavall, D
Zeman, F
Koller, M
Resch, M
Baessler, A
Maier, L.S
Wachter, R
Sossalla, S.T
author_sort Schach, C
collection PubMed
description BACKGROUND: Arrhythmias may often be a result of heart failure, but they can also cause left-ventricular systolic dysfunction (LVSD), thereby presenting as arrhythmia-induced cardiomyopathy (AIC). AIC-diagnosis is established retrospectively when LVSD normalizes or improves significantly over time following rhythm restoration. However, the prevalence and most importantly the time course of this relevant disease remain unclear and hence merit investigation to enable the correct diagnosis. PURPOSE: Therefore, our aim was to evaluate a) the occurrence of AIC in this clinical relevant cohort of patients with newly diagnosed and otherwise unexplainable LVSD and concomitant tachycardia and b) the time needed to fulfill the diagnostic criteria of AIC in order to facilitate a diagnostic algorithm. METHOD: We prospectively screened patients hospitalized for newly diagnosed and otherwise unexplainable LVSD (i.e. left ventricular ejection fraction (LVEF) <50%) and coexisting tachyarrhythmia (atrial fibrillation/flutter + heart rate (HR) >100/min) in 3 cardiological centers. Coronary angiography and cardiac magnetic resonance imaging were performed to exclude other causes for LVSD. Patients underwent a rhythm control strategy in accordance to the local clinical pathways. LVEF was assessed by echocardiography at presentation and at follow-up (FU) visits after 2, 4, and 6 months. Patients who lost sinus rhythm (SR) during FU were excluded. Patients with any increase of ≥15% in absolute EF or an EF ≥50% with an improvement of ≥10% after 6 months of FU were assigned to the AIC-group, which is a common definition of AIC. All others were assigned to an idiopathic DCM-group as final comparator. RESULTS: 68 patients were eligible, 18 of them were excluded: 1 lost to follow-up, 1 PCI, 2 COVID-19, 1 diagnosed cancer, 1 withdraw consent and 12 lost SR. Thus, our sample consists of a total of 50 patients. At presentation, mean±SD HR was 121±17/min. After rhythm therapy, HR normalized (67±10/min) and LVEF increased in both groups, see fig. 1. Surprisingly, only 9 patients did not fulfill the AIC-criteria in this specific collective resulting in a prevalence of 82% (95%-CI: 68% – 92%). This high prevalence of AIC underlines the importance of the disease. 2 and 4 months after rhythm intervention, 58% and 73% of patients fulfilled AIC-criteria (fig. 2). The sensitivity for detection of AIC by echocardiographic LVEF-measurement at months 2 and 4 of FU was 65% and 86% with a specificity of 100%, emphasizing that a FU of 6 months is necessary to certainly distinguish between AIC and idiopathic DCM. CONCLUSION: The prevalence of AIC in patients with newly diagnosed and otherwise unexplainable LVSD with concomitant tachycardia is 82%. Analysis of the time course of AIC clearly suggests that the final diagnosis cannot be established before 6 months after successful rhythm restoration. These results may help to improve diagnosis of AIC in daily clinical practice. FUNDING ACKNOWLEDGEMENT: Type of funding sources: None.
format Online
Article
Text
id pubmed-8767587
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-87675872022-01-20 Prevalence and time course of arrhythmia-induced cardiomyopathy in patients with newly diagnosed heart failure and concomitant tachyarrhythmia – the TACHY-HF pilot trial Schach, C Koertl, T Harler, B Muehlbeck, F Baum, P Meindl, C Lavall, D Zeman, F Koller, M Resch, M Baessler, A Maier, L.S Wachter, R Sossalla, S.T Eur Heart J Abstract Supplement BACKGROUND: Arrhythmias may often be a result of heart failure, but they can also cause left-ventricular systolic dysfunction (LVSD), thereby presenting as arrhythmia-induced cardiomyopathy (AIC). AIC-diagnosis is established retrospectively when LVSD normalizes or improves significantly over time following rhythm restoration. However, the prevalence and most importantly the time course of this relevant disease remain unclear and hence merit investigation to enable the correct diagnosis. PURPOSE: Therefore, our aim was to evaluate a) the occurrence of AIC in this clinical relevant cohort of patients with newly diagnosed and otherwise unexplainable LVSD and concomitant tachycardia and b) the time needed to fulfill the diagnostic criteria of AIC in order to facilitate a diagnostic algorithm. METHOD: We prospectively screened patients hospitalized for newly diagnosed and otherwise unexplainable LVSD (i.e. left ventricular ejection fraction (LVEF) <50%) and coexisting tachyarrhythmia (atrial fibrillation/flutter + heart rate (HR) >100/min) in 3 cardiological centers. Coronary angiography and cardiac magnetic resonance imaging were performed to exclude other causes for LVSD. Patients underwent a rhythm control strategy in accordance to the local clinical pathways. LVEF was assessed by echocardiography at presentation and at follow-up (FU) visits after 2, 4, and 6 months. Patients who lost sinus rhythm (SR) during FU were excluded. Patients with any increase of ≥15% in absolute EF or an EF ≥50% with an improvement of ≥10% after 6 months of FU were assigned to the AIC-group, which is a common definition of AIC. All others were assigned to an idiopathic DCM-group as final comparator. RESULTS: 68 patients were eligible, 18 of them were excluded: 1 lost to follow-up, 1 PCI, 2 COVID-19, 1 diagnosed cancer, 1 withdraw consent and 12 lost SR. Thus, our sample consists of a total of 50 patients. At presentation, mean±SD HR was 121±17/min. After rhythm therapy, HR normalized (67±10/min) and LVEF increased in both groups, see fig. 1. Surprisingly, only 9 patients did not fulfill the AIC-criteria in this specific collective resulting in a prevalence of 82% (95%-CI: 68% – 92%). This high prevalence of AIC underlines the importance of the disease. 2 and 4 months after rhythm intervention, 58% and 73% of patients fulfilled AIC-criteria (fig. 2). The sensitivity for detection of AIC by echocardiographic LVEF-measurement at months 2 and 4 of FU was 65% and 86% with a specificity of 100%, emphasizing that a FU of 6 months is necessary to certainly distinguish between AIC and idiopathic DCM. CONCLUSION: The prevalence of AIC in patients with newly diagnosed and otherwise unexplainable LVSD with concomitant tachycardia is 82%. Analysis of the time course of AIC clearly suggests that the final diagnosis cannot be established before 6 months after successful rhythm restoration. These results may help to improve diagnosis of AIC in daily clinical practice. FUNDING ACKNOWLEDGEMENT: Type of funding sources: None. Oxford University Press 2021-10-14 /pmc/articles/PMC8767587/ http://dx.doi.org/10.1093/eurheartj/ehab724.0762 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Abstract Supplement
Schach, C
Koertl, T
Harler, B
Muehlbeck, F
Baum, P
Meindl, C
Lavall, D
Zeman, F
Koller, M
Resch, M
Baessler, A
Maier, L.S
Wachter, R
Sossalla, S.T
Prevalence and time course of arrhythmia-induced cardiomyopathy in patients with newly diagnosed heart failure and concomitant tachyarrhythmia – the TACHY-HF pilot trial
title Prevalence and time course of arrhythmia-induced cardiomyopathy in patients with newly diagnosed heart failure and concomitant tachyarrhythmia – the TACHY-HF pilot trial
title_full Prevalence and time course of arrhythmia-induced cardiomyopathy in patients with newly diagnosed heart failure and concomitant tachyarrhythmia – the TACHY-HF pilot trial
title_fullStr Prevalence and time course of arrhythmia-induced cardiomyopathy in patients with newly diagnosed heart failure and concomitant tachyarrhythmia – the TACHY-HF pilot trial
title_full_unstemmed Prevalence and time course of arrhythmia-induced cardiomyopathy in patients with newly diagnosed heart failure and concomitant tachyarrhythmia – the TACHY-HF pilot trial
title_short Prevalence and time course of arrhythmia-induced cardiomyopathy in patients with newly diagnosed heart failure and concomitant tachyarrhythmia – the TACHY-HF pilot trial
title_sort prevalence and time course of arrhythmia-induced cardiomyopathy in patients with newly diagnosed heart failure and concomitant tachyarrhythmia – the tachy-hf pilot trial
topic Abstract Supplement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767587/
http://dx.doi.org/10.1093/eurheartj/ehab724.0762
work_keys_str_mv AT schachc prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT koertlt prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT harlerb prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT muehlbeckf prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT baump prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT meindlc prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT lavalld prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT zemanf prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT kollerm prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT reschm prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT baesslera prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT maierls prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT wachterr prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial
AT sossallast prevalenceandtimecourseofarrhythmiainducedcardiomyopathyinpatientswithnewlydiagnosedheartfailureandconcomitanttachyarrhythmiathetachyhfpilottrial